2023
Bacterial Sequencing Reads in Blood Exome Files from Melanoma and Cervical Cancer Patients are Associated with Cancer Recurrence
Quach J, Diaz M, Huda T, Kinskey J, Zaman S, Desantis J, Cios K, Blanck G. Bacterial Sequencing Reads in Blood Exome Files from Melanoma and Cervical Cancer Patients are Associated with Cancer Recurrence. Molecular Biotechnology 2023, 65: 1476-1484. PMID: 36653589, DOI: 10.1007/s12033-023-00663-9.Peer-Reviewed Original ResearchConceptsCervical cancer casesCervical cancer patientsCancer patientsExome filesCancer recurrenceCancer casesDisease-free survival probabilityImmunocompromised Cancer PatientsOverall survival resultsCancer clinical outcomesBacterial blood infectionsLower DFSClinical outcomesCervical cancerPrimary tumorSurvival resultsMelanoma casesBlood infectionSolid tumorsGreater riskPatientsBacteroides fragilisBloodPresence of bacteriaBacteroides species
2020
Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis
Zaman S, Chobrutskiy BI, Patel JS, Diviney A, Tu YN, Tong WL, Gill T, Blanck G. Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunology 2020, 33: 404-412. PMID: 32315578, DOI: 10.1089/vim.2019.0156.Peer-Reviewed Original ResearchConceptsT cellsRegion 3 sequencesSurvival rateTissue-resident T cellsCancer typesImmune receptor recombinationsResident T cellsWorse survival rateHuman papilloma virusWorse cancer outcomesTCGA data setsThymus cancerCancer Genome AtlasViral etiologyCancer outcomesDistinct survival ratesNeck cancerPapilloma virusDifferent cancer typesSolid tumorsTumor samplesExome filesGenome AtlasPancancer AnalysisCancer
2019
Targeting Trop-2 in solid tumors: future prospects
Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. OncoTargets And Therapy 2019, 12: 1781-1790. PMID: 30881031, PMCID: PMC6402435, DOI: 10.2147/ott.s162447.Peer-Reviewed Original ResearchAntibody-drug conjugatesTrop-2Clinical benefitClinical trialsTumor typesPlatinum-resistant urothelial cancerSmall cell lung cancerMultiple early-phase clinical trialsTriple-negative breast cancerEarly phase clinical trialsLimited treatment optionsTrop-2 expressionMultiple tumor typesUrothelial cancerTreatment optionsLung cancerBreast cancerSolid tumorsBaseline levelsCancer typesClinical useUpregulated expressionCancerTumorsNormal cells